PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of openopthaljLink to Publisher's site
 
Open Ophthalmol J. 2017; 11: 122–142.
Published online 2017 June 19. doi:  10.2174/1874364101711010122
PMCID: PMC5510558

Many Faces of Renin-angiotensin System - Focus on Eye

Abstract

The renin-angiotensin system (RAS), that is known for its role in the regulation of blood pressure as well as in fluid and electrolyte homeostasis, comprises dozens of angiotensin peptides and peptidases and at least six receptors. Six central components constitute the two main axes of the RAS cascade. Angiotensin (1-7), an angiotensin converting enzyme 2 and Mas receptor axis (ACE2-Ang(1-7)-MasR) counterbalances the harmful effects of the angiotensin II, angiotensin converting enzyme 1 and angiotensin II type 1 receptor axis (ACE1-AngII-AT1R) Whereas systemic RAS is an important factor in blood pressure regulation, tissue-specific regulatory system, responsible for long term regional changes, that has been found in various organs. In other words, RAS is not only endocrine but also complicated autocrine system. The human eye has its own intraocular RAS that is present e.g. in the structures involved in aqueous humor dynamics. Local RAS may thus be a target in the development of new anti-glaucomatous drugs. In this review, we first describe the systemic RAS cascade and then the local ocular RAS especially in the anterior part of the eye.

Keywords: ACE1, ACE2, Angiotensin II, Angiotensin (1-7), Eye, Glaucoma, Intraocular pressure, Mas receptor, Renin-angiotensin system

INTRODUCTION

Glaucoma, known for its destructive effects on the optic nerve axons and retinal ganglion cells, is one of the leading causes of blindness worldwide. In the next three years, approximately 80 million people around the world are predicted to be diagnosed with glaucoma [1]. This number is likely to be even higher due to the fact that glaucoma can be asymptomatic for a long time which makes it difficult to detect until it is severe [2, 3]. Glaucoma is a multifactorial optic neuropathy that can be roughly divided into two categories: open-angle glaucoma (POAG) and angle-closure glaucoma, both of which can cause visual field defects and irreversible vision loss [4-10].

While many genetic and biological risk factors have been identified, such as age, race and diabetes, the most fundamental reason why a patient is diagnosed with glaucoma is increased intraocular pressure (IOP) [6, 10-13]. The exact underlying mechanism for glaucoma development is still poorly known which makes it difficult to develop effective therapies for this destructive disease [14, 15]. As of today, the only treatment demonstrated to be effective to reduce disease progress is to lower IOP [16, 17]. That is to say, decrease of IOP by 30% reduces disease progress [18, 19]. In addition to the classical RAS that regulates blood pressure (BP), fluid volume as well as electrolyte balance and is also involved in inflammation, local tissue-specific RA-systems have been described in numerous organs including the human eye [20-24]. While the pathological mechanisms at molecular level are not yet well understood, local ocular RAS seems to have a role in ocular pathology and it has been associated to glaucoma and other eye disorders such as diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) [22, 25]. In this review, we describe the local ocular RAS cascade and concentrate on its potential role in the regulation of IOP while keeping the focus on the anterior part of the eye. A comprehensive survey of literature on PubMed was performed to collect the literature and eventually 258 articles were chosen based on their relevance. The following keywords were used and combined to narrow down the literature: IOP (41729), RAS (29132), tissue RAS (6080), angiotensin (116858), angiotensin I (8316), angiotensin II (59230), angiotensin (1-7) (1278), angiotensin (1-9) (73), angiotensin (3-4) (10) angiotensin converting enzyme 1 (238) and -2 (1453), Mas receptor (445), angiotensin receptor (17975), eye disease (5611), glaucoma (59565), diabetic retinopathy (DR) (26740), retinopathy of prematurity (ROP) (6638) and age-related macular degeneration (AMD) (13303).

RENIN-ANGIOTENSIN SYSTEM

Circulating Ras

The renin-angiotensin system is one of the oldest and most studied peptide cascades known today. The research concentrating on RAS started, in 1898, in Finland when Robert Tigerstedt and Per Bergman identified a renal BP elevating substance: renin [20, 26, 27]. Over 40 years later, more components of the RAS cascade were identified, one being the angiotensin peptide, first named as angiotonin, that Braun-Menéndez and Page reported to be formed from angiotensinogen by renin, an enzyme originated in the kidney [28-30]. 1970 was an important year in the RAS research as its role in BP and fluid balance regulator was understood which led to the development of the first antihypertensive medications such as captopril that blocks the formation of Ang II by inhibiting ACE1 [20, 28]. Later more antihypertensive drugs were designed and developed, one of which was Ang II type 1 receptor blocker (ARB) that blocks the vasoconstrictive effects of Ang II through its main receptor [31].

Multiple peptides, enzymes and receptors have been identified since the first clue of the existence of RAS. One of the important and fairly recent findings was the identification of a new receptor type: MasR whose activities, such as vasodilatation, antifibrosis and antiproliferation, are opposite to those of angiotensin II type 1 receptor (AT1R). This discovery led to the division of RAS into two central axes: ACE1-Ang II-AT1R and ACE2-Ang(1-7)-MasR giving antihypertensive drug development new angles to focus on [32-34] as chronic imbalances of these main axes can potentially lead to pathological events of e.g. renal, cardiovascular and central nervous system [35]. In time, RAS has truly evolved from simple linear pathway, having only one known substrate, two proteases, two peptides and one receptor, into a complex cascade consisting of multiple mediators, functionally versatile enzymes and various receptors that are activated by several angiotensin peptides [36-40]. Figure 1 shows the full extent of the RAS cascade known today.

The classical RAS cascade starts with highly specific aspartyl protease renin that cleaves the peptide bond between Leu10 and Val11 at the amino terminus of angiotensinogen (AGT), a 225 amino acids long α-glycoprotein, to form angiotensin I (Ang I) [28, 42, 43]. AGT is mainly synthesized and released from liver but other organs such as heart, kidney and adipose tissue can also produce it [44]. Inflammation, insulin and estrogens among other things can stimulate the synthesis of AGT [42]. Renin is mainly synthesized in kidney as an inactive prorenin that is activated by either cathepsin B or proconvertase and secreted from the juxtaglomerular apparatus [28, 42, 43] in response to either decreased arterial BP, decreased sodium levels or increased activity of sympathetic nervous system [45-47]. Both renin and prorenin can bind to (pro)renin receptor ((P)RR) and thus mediate vasoconstrictive effects [42, 48].

Ang I, a weak prohormone and vasoconstrictor can be further cleaved to form Ang II. Different enzymes can form Ang II from Ang I: e.g. ACE1, tonin [49], trypsin [50], kallikrein [51], cathepsin G [52] and chymase [53-55]. ACE1 is present in many tissues as well as in biological fluids e.g. in plasma [56-58]. In order to work, ACE1 needs Zn2+ in complex with activated water molecule in its active site [59] and chloride to improve substrate binding [60]. This main enzyme acting on Ang I, removes two amino acids (His-Leu) from the carboxyl terminus of Ang I to form one of the central peptides of RAS cascade: Ang II. In addition to being an important enzyme in RAS, ACE1 also acts in kallikrain-kinin system [42, 45]. Other enzymes mentioned above are regarded as alternative pathways for Ang II generation [61-63] which are important in physiological and pathophysiological conditions [64, 65]. However, these pathways are not discussed further in this review.

In 1940, Ang II an octapeptide also known as Ang (1-8) was first isolated and characterized as a potent vasoconstrictor that raises BP and regulates e.g. electrolyte balance, vascular tone and thirst [29, 30, 43]. It stimulates the release of aldosterone and vasopressin and exerts its harmful actions, such as vasoconstriction, fibrosis and inflammation via G-protein coupled AT1R [42, 43, 66-68]. Furthermore, Ang II can also activate angiotensin II type 2 receptors (AT2R) whose activities are thought to oppose those of AT1R [31, 42, 43]. AT2Rs are regarded as protective receptors as they may elicit vasodilatory, antihypertensive, proapoptotic as well as antiproliferative effects [53, 69] and as they can bind directly to AT1R thus inhibiting signaling through it [31]. ACE inhibitors are used as antihypertensive medications as they oppose the harmful effects of Ang II via AT1R by blocking the conversation of Ang I to Ang II by ACE1 thus elevating the levels of Ang(1-7) [42, 43].

Angiotensin II can then be further cleaved by ACE1 or aminopeptidase A to generate angiotensin III (Ang III) or by aminopeptidase N to form angiotensin IV (Ang IV) [20, 28, 42, 43]. Ang IV can also be generated from Ang III by aminopeptidases N, M and B [28, 43]. Ang III exerts its vasoconstrictive actions via the same receptors as Ang II (higher affinity to AT2R) whereas Ang IV prefers angiotensin II type 4 receptors (AT4R) which are related to cognitive functions and proliferative effects and which are found e.g. in brain, lung and kidney [20, 70, 71]. Ang IV can also elicit its biological effects, including renal vasodilatation, hypertrophy and regulation of cell growth, through activation of AT1R [72].

Cleavage of one amino acid residue (Phe) from carboxyl terminus of Ang I by ACE2 [73], carboxypeptidase A or cathepsin A [74, 75] generate angiotensin (1-9) (Ang(1-9)) whose main biological functions are to release arachidonic acid, promote nitric oxide formation and increase bradykinin activity [74]. Ang(1-9) may also reduce BP, decrease hypertension [76] and possibly play a role in inhibition of platelet function [77]. The formation of Ang(1-9) is thought to be dependent on ACE2 activity [73, 78] and it has been suggested that Ang(1-9) could mediate its actions by activating the AT2 receptors [76, 79]. ACE2 (42% sequence identity to ACE1) was first cloned in 2000 and has since been identified in multiple organs such as kidney, heart, brain, liver and lung [42, 73, 80-82]. ACE2 has been shown to convert Ang I to Ang(1-9) [73] and most importantly to form Ang(1-7) from Ang II [42, 80, 83-85]. This enzyme has zinc metallopeptidase consensus sequence (HEXXH) in its active site and like its homologue ACE2 activity is also regulated by the presence of chloride ions [42]. ACE2 cleaves only one amino acid residue from Ang II thus enhancing Ang(1-7) formation and leaving less substrate to ACE1 to act on [42, 82]. Furthermore, ACE inhibitors used as antihypertensive medications do not block ACE2 activity making this enzyme together with Ang(1-7) and MasR the focus of the research regarding RAS and cardiovascular drug development [80, 86].

Ang(1-7) that was first thought to be devoid of biological function can be generated from Ang II by ACE2, prolyl-endopeptidase and prolyl-carboxypeptidase [20, 43, 80, 87] or from Ang(1-9) by ACE1 and NEP [83]. It can also be metabolized directly from Ang I or from prohormone Ang(1-12) bypassing the biosynthesis of Ang II [43, 87]. Moreover, Ang(1-7) can be further metabolized into smaller peptides such as angiotensin (1-5) or angiotensin (2-7) [28].

Ang(1-7) is known to have functions opposite to those of Ang II [43]. Although, Ang(1-7) may interact with AT1R and AT2R [76, 79, 84, 86], this peptide elicits its vasodilating and antiproliferatory effects through activation of its main receptor MasR [20, 42, 79, 84]. MasR is a G-protein coupled receptor [88] that was first described as a proto-oncogene [89]. This receptor has been found e.g. in eye, central nervous system, kidney, heart and brain [88, 90-93] and is known to act antagonistically to AT1R [53]. Due to its antiarrhythmogenic, antithrombogenic, growth-inhibitory and vasoconstrictive inhibitory properties, Ang(1-7) is seen as a protective peptide that acts as a counterregulator within RAS [38-40]. Interestingly, the association between Ang(1-7) and pathology of multiple diseases such as hypertension [84, 86, 87, 94-98] and diabetic nephropathy [46, 99, 100] makes this peptide a potential target for drug development.

Interestingly, in addition to ACE2-Ang(1-7)-MasR axis, a newly described member of RAS, angiotensin(3-4) (Ang(3-4)) counteracts the traditional ACE1-Ang II-AT1R pathway both systemically and locally[101]. Ang(3-4) has antihypertensive effects that are mediated via AT2 receptors. This dipeptide is antiproliferative and vasodilating and it inhibits ACE1. Furthermore, it is effective when administered orally, as it permeates intestinal cells relatively easily, lowers Ang II and aldosterone levels in plasma and inhibits ACE1. Ang(3-4) levels are higher in healthy individuals than in hypertensive patients [101]. All in all, it remains open what are the therapeutic possibilities of Ang(3-4) and its potential functions in local RA-systems beyond renal tissue such as in eye.

In addition to previously mentioned angiotensin peptides and enzymes, there are several different peptidases, proteases and small peptides that are part of the RAS cascade but are not discussed in this review. However, all of these enzymes and smaller angiotensin peptides are shown in Fig. (11). In addition, the kallikrein-kinin system that is also shown in Figure 1 and that interacts with RAS is not discussed in detail in this review.

Fig. (1)
The renin-angiotensin system. The two main axes of RAS are highlighted with colors. ACE2-Ang(1-7)-MasR axis (red lines) counterbalances the harmful effects of the ACE1-Ang II-AT1R axis (blue lines). ACE1: Angiotensin-converting enzyme 1; ACE2: Angiotensin-converting ...

TISSUE RAS

Even though circulatory RAS has many important roles in human body, various organs have their own tissue specific RA-systems that elicit long term changes and local effects such as growth, proliferation and protein synthesis at organ level [20, 31, 64]. Ganten et al. 1971 were the first researchers to show that RAS is also an organ specific system that has important regulatory roles at tissue level [102]. For example, heart, brain, intestine and even the human eye have their own local RA-systems [6, 31, 43].

Later, local RA-systems were divided into two groups based on the origin of Ang II: extrinsic RAS gets its Ang II from the circulation whereas intrinsic RAS synthesises its own Ang II locally [103]. Although some of the local RA-systems depend on interactions with circulatory RAS to fully operate, in many organs tissue RA-systems prefer to function independently [43]. Indeed local tissue-specific RA-systems can independently produce different components of RAS thus proving that RAS is more than just an endocrine circulatory system and that it regulates more functions than suggested earlier [6, 31, 43, 64].

Local ocular RAS has been found partly in the eye. So far all of the central components of RAS including the components of the two main axes: ACE1-Ang II-AT1R and ACE2-Ang(1-7)-MasR have been identified in different eye structures in various species [6, 9]. In the human eye, elements of the two main axes have been identified in retinal as well as in non-retinal ocular structures [6, 93, 104]. Tables (11 and 22) summarize the localization of RAS peptides, enzymes and receptors in non-retinal ocular structures of the human eye.

Table 1
Renin-angiotensin system components in bulbar conjunctiva, cornea, trabecular meshwork, aqueous humor, iris, ciliary body and non-pigmented ciliary epithelium, of the human eye.
Table 2
Renin-angiotensin system components in lens, tears and lacrimal gland, vitreous, optic nerve head and sclera of the human eye.

Even though RAS is present in the human eye, its function and significance in ocular pathophysiology is still unknown. Whether angiotensin peptides found in the human eye originate partially from the blood compartment or are synthesized locally has been the topic of the debate [117]. Circulating angiotensins e.g. Ang I and Ang II cannot pass the blood-brain barrier and cannot reach the vitreous fluid when blood-retina barrier in the eye is intact [24, 117, 128, 129]. Moreover, in porcine eyes Ang I and Ang II levels are shown to be 5 to 100-fold higher than those found from diffusion of blood [117] and in comparison to plasma ACE1 activity are higher in ocular structures of pig and rabbit eyes [130, 131]. However, intraocular RAS may play a role in the regulation of IOP through its effects on AH dynamics [9, 31]. Ang II has been suggested to increase AH secretion via AT1R [122]. Animal studies as well as studies on different patient groups indicate that systemic antihypertensive RAS-inhibiting medications such as ACE inhibitors [103, 132, 133], ARBs [134-136] and renin inhibitors [137], reduce IOP. Moreover, intraocular RAS and its actions have been linked to various eye diseases [6, 138].

EYE DISEASES AND LOCAL RAS

Glaucoma

Glaucoma is a multifactorial long-term neurodegenerative disorder which can be characterized by the non-apoptotic and apoptotic death of retinal ganglion cells and the loss of retinal nerve fibers all of which lead to loss of visual field [6, 7, 9, 10]. The death of retinal ganglion cells leads to increased IOP which is the most important risk factor for the development of glaucoma and the only risk factor amenable to treatment [15, 138, 139]. Increased IOP can lead to ischemia, mechanical impairment, oxidative stress and optic nerve inflammation [140]. However, not every patient with high IOP develops glaucoma nor do all the glaucoma patients have increased IOP [15]. Several other risk factors such as age, family history, diabetes, vascular dysfunction and systemic hypertension have also been linked to glaucoma [6, 9-11, 139, 141-144]. In addition to genetic and environmental factors, epigenetics also affect the signaling pathways that are held responsible for glaucoma progression [145, 146].

IOP is maintained by a homeostatic balance between formation and outflow of AH. In the healthy human eye, the flow of AH against resistance generates an IOP of about 15 mmHg (range 9-21 mmHg) [147-149]. Diurnal variation of IOP is about 5 mmHg in healthy subjects. Higher IOP values are normally measured in the morning. Transient postural IOP variations can be even twofold e.g. in yoga practioners during sirsasana, headstand posture [150]. In addition, physical exercise can influence ocular pressure [151, 152]. Typically aerobic exercise reduces IOP due to the better ocular circulation [153] whereas anaerobic exercise elevates IOP due to the transient obstructed ocular circulation [154]. The pressure is needed to maintain the optical and refractive properties of the eye [148, 149, 155]. One of the other fundamental functions of IOP is to maintain the right shape of the eye [148, 155]. The normal AH formation rate (2.5-2.8µL/min) is lower while sleeping (1.5µL/min) and can be reduced with ageing and in some systemic diseases such as in diabetes [9, 139, 156].

AH is a mixture of different electrolytes, growth factors, proteins, amino acids, cytokines, inorganic and organic solutes [157-161]. Circulating AH not only sustains and nourishes non-vascularized eye structures e.g. cornea and lens but it also removes excretory products, transports neurotransmitters and enables mediators and inflammatory cells to circulate in the eye [9, 156]. Ciliary body epithelial is the site of AH production [147]. Although two passive processes: diffusion and ultrafiltration, that require no cellular activity nor energy [148], also participate on AH production [162], active secretion accounts for 80-90% of the total AH formation [155, 156, 163]. Active and selective trans-cellular transport of ions and molecules across the epithelium against concentration gradient requires energy that is generated by hydrolysis of adenosine triphosphate (ATP) by Na+/K+ ATPase. Na+ and K+ activate ATP hydrolysis whereas different molecules such as dinitrophenol and vanadate inhibit Na+/K+ ATPase [156, 164, 165]. Moreover, active transport of Na+ into the posterior chamber causes water flow from the stromal pool into the posterior chamber and two aquaporins (AQP1 and AQP4) have been shown to contribute to AH formation [166, 167]. Other ions and molecules that are actively transported across the epithelium include Cl-, HCO3-, ascorbic acid and certain amino acids. However, active transport of these components occur to a lesser extent [156, 166, 168-170]. After the production and secretion into the posterior chamber, AH flows between the lens and the iris into the anterior chamber from where it will be disposed [157, 171, 172].

From the anterior chamber, AH flows through the trabecular meshwork and the canal of Schlemm into the venous blood system [147]. AH can exit the eye through the trabecular, the uveoscleral or the uveolymphatic pathways [139] from which the first is pressure-dependent main route of drainage accounting for 90% of all AH outflow [9, 139, 173]. Aqueous humor flows through the porous trabecular meshwork passively when appropriate IOP level is reached and AH gets filtered in the process [174]. The actin cytoskeleton and the adhesions of trabecular meshwork cells affect the fluid outflow through the trabecular meshwork [175]. The first route of drainage can also be described as the conventional pathway [176] which rate limiting step is the flow through the inner wall of Schelmm's canal [58]. From Schelmm's canal dozens of collector channels connect with aqueous veins through which AH flows into the circulatory system [177, 178].

In addition to trabecular pathway some AH exit the eye through the uveosscleral route [179]. In comparison to the trabecular pathway the uveoscleral pathway is relatively independent of IOP and undergoes age-dependent changes [173, 179]. The uveoscleral route of drainage can also be described as the unconventional pathway in which AH drains through the ciliary muscle and exits through the supraciliary space across the anterior/posterior sclera into the choroidal vessels and returns to systemic circulation [180, 181]. The rate limiting step in uveoscleral pathway is the flow through the ciliary muscle [179].

The third route of drainage that is thought to work as a backup system is located in channels of the ciliary body stroma and intestinal space between ciliary muscle bundles [182]. Other minor outflow pathways via iris vessels, corneal endothelium and anterior vitreous body have also been described [183]. As IOP is the net sum of aqueous humor formation and outflow, anti-glaucomatous treatments aim to lower IOP by either decreasing the rate of AH formation or by increasing AH drainage [184]. Lowering IOP by laser therapy, ocular hypotensive medications or surgical procedures is currently the only therapeutic tool to treat this devastating disease [6, 9, 10, 28].

Some studies have suggested that drugs affecting RAS by blocking its action e.g. ACE inhibitors [132, 133, 185] and ARBs [134, 135] might be potential anti-glaucomatous drugs in the future. Animal studies also support these findings [103, 133, 135-137]. ACE inhibitors can affect IOP levels through their actions on AH dynamics. These inhibitors can decrease Ang II levels in AH, thus affecting the uveoscleral outflow [118, 186, 187], and slow down AH formation by lowering blood flow in the ciliary body [188] which is the primary site of AH production. ACE inhibitors also act through kallikrein-kinin system. By blocking the breakdown of bradykinin these inhibitors support prostaglandin synthesis which in turn lowers IOP by elevating uveoscleral outflow [189-191]. By preventing bradykinin breakdown ACE inhibitors also cause vasodilatation as their actions lead to increased nitric oxide formation by endothelial cells. Both prostaglandins and nitric oxide being vasodilatory also inhibit the synthesis of vasoconstrictive peptide endothelin-1 [192-195]. In addition, ARBs have been suggested to elevate uveoscleral outflow and slow down cell death of retinal ganglion cells [195, 196].

RAS components have also been identified in central structures of the eye responsible for AH formation and RAS activity has been reported in cultured human non-pigmented ciliary epithelial cells [6, 120, 122]. Interestingly, Ang(1-7) that acts via MasR and ACE2 activating diminazene aceturate (DIZE) have been reported to have positive effects on glaucoma by decreasing IOP [41, 197, 198]. Indeed, as Ang(1-7) actions are opposite to those of Ang II, this heptapeptide is thought to have beneficial effects on the human body including the eye. Moreover, ACE2 activating compounds are considered as novel pharmacotherapeutic agents [7, 41, 199-201].

Whereas Ang(1-7) and ACE2 activation are thought to have positive effects on IOP, Ang II has suggested to have negative effects on the human eye even though some of the results are controversy. Ang II augments cell proliferation in trabecular meshwork and increases collagen synthesis in vivo [187]. Intracamerally administered Ang II also lowers uveoscleral outflow [41] whereas in cats intravenously administered Ang II decreases IOP [202]. Ang II can also act as a secretagogue peptide in non-pigmented ciliary cells [122] as it promotes potassium ion channel activity through Ca2+ signaling [203] and causes higher cytoplasmic sodium concentration by activating Na+/H+ exchange [163]. Imbalances in sodium handling in ciliary and renal tubular epithelium might explain the association between glaucoma and hypertension [204]. On the other hand, defects in autoregulation of the posterior ciliary circulation [205] and microvascular damage affecting the optic nerve blood supply [206] both caused by hypertension could also explain the coexistence of hypertension and glaucoma. Furthermore, hypotensive periods caused by antihypertensive medications can also lead to injured optic nerve fibers [207].

Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the most leading causes of blindness worldwide and one of the most common microvascular complications of diabetes [208-210]. As diabetes becomes more and more common among adults, the incidences of DR are predicted to rise dramatically. Nearly all patients with type 1 diabetes and almost 60% of patients suffering from type 2 diabetes show some signs of DR later in diabetes [211]. Many factors such as high BP, hyperglycemia, hyperlipidemia, age and oxidative stress play a role in the development of DR [212, 213]. The early state of the disease is described as non-proliferative DR (NPDR) in which microaneurysms are formed due to the weakened retinal blood vessels and blood-retinal barrier breaks down. After the formation of microaneurysms, fluid can leak into retina causing swelling of the macula. Proliferative DR (PDR) is used of more serious and advanced form of DR. In addition to the symptoms seen in NPDR, PDR also manifests blood vessel growth on the surface of the retina and into the vitreous [209, 214, 215].

Studies have shown that RAS, especially Ang II mediated actions through AT1R, is involved in the progression of DR [31, 52, 94, 216-218]. Over-expression of Ang II and prorenin as well as vascular endothelial growth factor (VEGF) exists in vitreous humor of individuals suffering from DR [24, 219-221]. Ang II promotes angiogenesis and possibly increases the risk of neovascularization and hyperpermeability by increasing the retinal blood vessel permeability [219, 220, 222-225]. Furthermore, (P)RR has been linked to the development of DR through its direct effects on expression of angiogenic molecules in retinal cells [226-229]. RAS involvement in angiogenesis has promoted research concentrating on the potential therapeutic role of RAS inhibitors in DR [230]. Blocking the RAS cascade can actually slow down the progression of the disease [231-233] especially in normotensive patients [234]. In patients with type 1 and type 2 diabetes, a link between decreased blood pressure and reduced DR progression has been described [235, 236]. RAS inhibitors can reduce the risk of DR and possibly affect the progression of the disease in diabetic patients [229]. In addition, ACE2 activation reduces retinal ganglion cell death in hyperglycemic rats [198]. Afterall, more basic research and randomized clinical trials are needed in the future to resolve the exact mechanism of action of RAS compounds.

Age-related Macular Degeneration

Age-related macular degeneration (AMD) is a major cause of irreversible vision loss among aged population. This devastating disease is the reason why 8.7% of people worldwide suffer from blindness [237]. Whereas dry AMD is characterized with the significant loss of photoreceptors leading to the loss of central vision, wet form of AMD causes choroidal neovascularization in which pathologically grown blood vessels penetrate Bruch's membrane and populate retina. 90% of AMD cases are diagnosed as dry form of AMD. Interestingly, in addition to many risk factors such as old age, smoking, systemic hypertension as well as environmental and genetic factors imbalances in RAS cascade have also been connected to the development of AMD [6, 22, 208, 238-241].

Circulating RAS is known for its role as the regulator of BP and defects in RAS cascade can lead to systemic hypertension which in turn raises the risk of developing AMD. Furthermore, Ang II modulates retinal pigment epithelium which suggests that impairment in RAS regulation might affect the function of retinal pigment epithelium as well as the viability of photoreceptors. Ang II affects retinal angiogenesis which in turn suggests that this vasoconstrictive octapeptide might also be involved in choroidal neovascularisation [6, 238]. The activation of two types of RAS receptors: AT1R and (P)RR have also been linked to the development of AMD [242, 243]. Animal studies have shown that losartan an AT1R antagonist [244], ARBs [245], ACE inhibitors [239] and (P)RR inhibitors [243] have positive effects on AMD as these compounds can reduce choroidal neovascularization by suppressing inflammatory agents. As of today, no effective therapies are available for treatment of dry AMD [246]. However, understanding the role of RAS in the development of AMD might help us manage and slow down the progression of this disease [138, 247].

Retinopathy of Prematurity

Whereas AMD affects elderly people, retinopathy of prematurity (ROP) is an eye disease that only affects premature newborns (born <32 weeks) and can lead to permanent vision loss [25, 238]. The main risk factors identified for development of ROP are lower gestational age and low birth weight (<1.5 kg). In industrialized countries, roughly two-thirds of newborns with birth weight less than 1.25 kg manifest some signs of ROP. All the risk factors identified for this disease correlate with retinal immaturity at birth [25, 248]. ROP can be characterized as neovascular disease in which retinal neovascularisation leads to several complications such as macula dragging, tractional retinal detachment and vitral haemorrhage [238]. When a premature newborn is brought into a high oxygen environment, the growth of retinal blood vessels that expand from the optic nerve halts. After oxygen conditions are normalized, the inner retinal vasculature fails to regain the normal growth which in turn creates an avascular area and leads to neovascularisation, epiretinal angiogenesis and possibly loss of vision field [249]. Today, laser photocoagulation and intravitreal injections of bevacizumab or pegaptanib are used as therapeutic tools to manage ROP [25, 250, 251].

Interestingly, studies have shown that newborns that are suffering from ROP have had increased levels of serum prorenin [252], ocular renin [253, 254] as well as increased AT1R and AT2R expression [253]. Moreover, studies using animal models with oxygen induced retinopathy have shown that ACE inhibitors and AT1R antagonist treatments during the normal air conditions can reduce pathological angiogenesis in retina [253, 255-257]. However, the effects of treating retinal angiogenesis with AT2R antagonist and the possible role of AT2R in retinal vascular pathology are still uncertain [223, 254, 256, 258]. Nath et al. studied RAS involvement in ROP in infant patients (n=44) suffering from ROP as well as in rats with oxygen induced retinopathy. They found significantly higher levels of AGT, ACE1 and Ang II, in vitreous humor of infants suffering from ROP compared to healthy controls. Renin levels were also increased but the difference was found to be statistically not significant. In animal studies up-regulated mRNA expressions for renin, AGT, ACE1 and AT1R were found in retina of the rats suffering from oxygen induced retinopathy. Furthermore, ACE inhibitor (lisinopril) and ARB (telmisartan) were shown to suppress the over-activation induced vascular and retinal functional changes in ROP [25]. However, further research is needed to understand the involvement of RAS in the development and treatment of ROP.

CONCLUSION

Interestingly, in addition to circulating RAS that is involved in BP regulation and inflammation, local tissue specific RAS has been identified in many organs of the human body including the eye. It has been detected in various parts of the eye even in the structures involved in aqueous humor formation and outflow. These intriguing observations should promote more research concentrating on the possible role of local RAS in aqueous humor dynamics and thus IOP regulation. However, factors such as retinal ganglion cell death due to other reasons than pressure might also be involved in glaucoma progression. Identification of the second counter-regulating axis of RAS (ACE2-Ang(1-7)-MasR) has already brought new opportunities into light, and compounds affecting Ang(1-7) synthesis as well as MasR and ACE2 activity offer new and exciting possibilities for ocular pharmacology in the future.

ACKNOWLEDGEMENTS

Glaukoomatukisäätiö Lux (AV) and Finska Läkaresällskapet Einar och Karin Stroems Stiftelse (HV). Author contributions: MH collected the literature, prepared the tables and the figure and wrote the preliminary version of the review article; HV revised the text; and AV revised the text and submitted the article.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The author confirms that this article content has no conflict of interest.

REFERENCES

1. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006;90(3):262–267. doi: 10.1136/bjo.2005.081224. [PMC free article] [PubMed] [Cross Ref]
2. Leite M.T., Sakata L.M., Medeiros F.A. Managing glaucoma in developing countries. Arq. Bras. Oftalmol. 2011;74(2):83–84. doi: 10.1590/S0004-27492011000200001. [PMC free article] [PubMed] [Cross Ref]
3. Rotchford A.P., Kirwan J.F., Muller M.A., Johnson G.J., Roux P. Temba glaucoma study: a population-based cross-sectional survey in urban South Africa. Ophthalmology. 2003;110(2):376–382. doi: 10.1016/S0161-6420(02)01568-3. [PubMed] [Cross Ref]
4. Friedman D.S., Wolfs R.C., O’Colmain B.J., Klein B.E., Taylor H.R., West S., Leske M.C., Mitchell P., Congdon N., Kempen J., Eye Diseases Prevalence Research Group Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004;122(4):532–538. doi: 10.1001/archopht.122.4.532. [PMC free article] [PubMed] [Cross Ref]
5. Day A.C., Baio G., Gazzard G., Bunce C., Azuara-Blanco A., Munoz B., Friedman D.S., Foster P.J. The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. Br. J. Ophthalmol. 2012;96(9):1162–1167. doi: 10.1136/bjophthalmol-2011-301189. [PubMed] [Cross Ref]
6. Giese M.J., Speth R.C. The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease. Pharmacol. Ther. 2014;142(1):11–32. doi: 10.1016/j.pharmthera.2013.11.002. [PubMed] [Cross Ref]
7. Foureaux G., Nogueira J.C., Nogueira B.S., Fulgêncio G.O., Menezes G.B., Fernandes S.O., Cardoso V.N., Fernandes R.S., Oliveira G.P., Franca J.R., Faraco A.A., Raizada M.K., Ferreira A.J. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest. Ophthalmol. Vis. Sci. 2013;54(6):4296–4306. doi: 10.1167/iovs.12-11427. [PMC free article] [PubMed] [Cross Ref]
8. Liu T., Xie L., Ye J., Liu Y., He X. Screening of candidate genes for primary open angle glaucoma. Mol. Vis. 2012;18:2119–2126. [PMC free article] [PubMed]
9. Vaajanen A., Vapaatalo H. Local ocular renin-angiotensin system - a target for glaucoma therapy? Basic Clin. Pharmacol. Toxicol. 2011;109(4):217–224. doi: 10.1111/j.1742-7843.2011.00729.x. [PubMed] [Cross Ref]
10. Weinreb R.N., Khaw P.T. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720. doi: 10.1016/S0140-6736(04)16257-0. [PubMed] [Cross Ref]
11. Tuulonen A., Forsman E., Hagman J., Harju M., Kari O., Lumme P., Luodonpää M., Määttä M., Saarela V., Vaajanen A., Komulainen J. [Update on Current Care Guideline: Glaucoma]. Duodecim. 2015;131(4):356–358. [PubMed]
12. Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123–1129.e3. doi: 10.1016/j.ophtha.2007.10.031. [PubMed] [Cross Ref]
13. Kersey T., Clement C.I., Bloom P., Cordeiro M.F. New trends in glaucoma risk, diagnosis & management. Indian J. Med. Res. 2013;137(4):659–668. [PMC free article] [PubMed]
14. Weinreb R.N., Aung T., Medeiros F.A. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911. doi: 10.1001/jama.2014.3192. [PMC free article] [PubMed] [Cross Ref]
15. Schmidl D., Schmetterer L., Garhöfer G., Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J. Ocul. Pharmacol. Ther. 2015;31(2):63–77. doi: 10.1089/jop.2014.0067. [PMC free article] [PubMed] [Cross Ref]
16. Hirooka K., Baba T., Fujimura T., Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am. J. Ophthalmol. 2006;142(3):523–525. doi: 10.1016/j.ajo.2006.04.020. [PubMed] [Cross Ref]
17. Boland M.V., Ervin A.M., Friedman D.S., Jampel H.D., Hawkins B.S., Vollenweider D., Chelladurai Y., Ward D., Suarez-Cuervo C., Robinson K.A. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2013;158(4):271–279. doi: 10.7326/0003-4819-158-4-201302190-00008. [PubMed] [Cross Ref]
18. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 1998;126(4):487–497. doi: 10.1016/S0002-9394(98)00223-2. [PubMed] [Cross Ref]
19. Collaborative Normal-Tension Glaucoma Study Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 1998;126(4):498–505. doi: 10.1016/S0002-9394(98)00272-4. [PubMed] [Cross Ref]
20. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008;264(3):224–236. doi: 10.1111/j.1365-2796.2008.01981.x. [PubMed] [Cross Ref]
21. Wilkinson-Berka J.L., Kelly D.J., Rong P., Campbell D.J., Skinner S.L. Characterisation of a thymic renin-angiotensin system in the transgenic m(Ren-2)27 rat. Mol. Cell. Endocrinol. 2002;194(1-2):201–209. doi: 10.1016/S0303-7207(02)00217-4. [PubMed] [Cross Ref]
22. Kurihara T., Ozawa Y., Ishida S., Okano H., Tsubota K. Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int. J. Inflam. 2012; Available from: https://www.hindawi.com/journals/iji/2012/581695/ 2012 doi: 10.1155/2012/581695. 2012: 581695. [PMC free article] [PubMed] [Cross Ref]
23. Igic R., Robinsson C., Erdos E. Angiotensin I converting enzyme activity in the choroid plexus and in the retina. New York: Pergamon Press; 1977. [Cross Ref]
24. Danser A.H., van den Dorpel M.A., Deinum J., Derkx F.H., Franken A.A., Peperkamp E., de Jong P.T., Schalekamp M.A. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 1989;68(1):160–167. doi: 10.1210/jcem-68-1-160. [PubMed] [Cross Ref]
25. Nath M., Chandra P., Halder N., Singh B., Deorari A.K., Kumar A., Azad R., Velpandian T. Involvement of renin-angiotensin system in retinopathy of prematurity - a possible target for therapeutic intervention. PLoS One. 2016;11(12):e0168809. doi: 10.1371/journal.pone.0168809. [PMC free article] [PubMed] [Cross Ref]
26. Robert T., Per B. Niere und Kreislauf. Skand. Arch. Physiol. 1898;8:223–271. doi: 10.1111/j.1748-1716.1898.tb00272.x. [Cross Ref]
27. Bader M., Ganten D. Update on tissue renin-angiotensin systems. J. Mol. Med. (Berl.) 2008;86(6):615–621. doi: 10.1007/s00109-008-0336-0. [PubMed] [Cross Ref]
28. Vaajanen A., Luhtala S., Oksala O., Vapaatalo H. Does the renin-angiotensin system also regulate intra-ocular pressure? Ann. Med. 2008;40(6):418–427. doi: 10.1080/07853890802043924. [PubMed] [Cross Ref]
29. Braun-Menendez E., Fasciolo J.C., Leloir L.F., Muñoz J.M. The substance causing renal hypertension. J. Physiol. 1940;98(3):283–298. doi: 10.1113/jphysiol.1940.sp003850. [PubMed] [Cross Ref]
30. Page I.H., Helmer O.M. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J. Exp. Med. 1940;71(1):29–42. doi: 10.1084/jem.71.1.29. [PMC free article] [PubMed] [Cross Ref]
31. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006;86(3):747–803. doi: 10.1152/physrev.00036.2005. [PubMed] [Cross Ref]
32. Paulis L., Unger T. Novel therapeutic targets for hypertension. Nat. Rev. Cardiol. 2010;7(8):431–441. doi: 10.1038/nrcardio.2010.85. [PubMed] [Cross Ref]
33. Ferrario C.M. ACE2: more of Ang-(1-7) or less Ang II? Curr. Opin. Nephrol. Hypertens. 2011;20(1):1–6. doi: 10.1097/MNH.0b013e3283406f57. [PubMed] [Cross Ref]
34. Ferreira A.J., Murça T.M., Fraga-Silva R.A., Castro C.H., Raizada M.K., Santos R.A. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int. J. Hypertens Available from: https://www.hindawi.com/journals/ijhy/2012/147825/ . 2012 2012: 147825. [PMC free article] [PubMed]
35. Ferreira A.J., Santos R.A., Bradford C.N., Mecca A.P., Sumners C., Katovich M.J., Raizada M.K. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55(2):207–213. doi: 10.1161/HYPERTENSIONAHA.109.140145. [PMC free article] [PubMed] [Cross Ref]
36. Lazartigues E. A map and new directions for the (pro)renin receptor in the brain: focus on “A role of the (pro)renin receptor in neuronal cell differentiation”. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009;297(2):R248–R249. doi: 10.1152/ajpregu.00287.2009. [PubMed] [Cross Ref]
37. Santos R.A., Ferreira A.J., Simões E Silva A.C., Silva A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol. 2008;93(5):519–527. doi: 10.1113/expphysiol.2008.042002. [PubMed] [Cross Ref]
38. Chappell M.C. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension. 2007;50(4):596–599. doi: 10.1161/HYPERTENSIONAHA.106.076216. [PubMed] [Cross Ref]
39. Santos R.A., Ferreira A.J. Angiotensin-(1-7) and the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 2007;16(2):122–128. doi: 10.1097/MNH.0b013e328031f362. [PubMed] [Cross Ref]
40. Simões e Silva A.C., Pinheiro S.V., Pereira R.M., Ferreira A.J., Santos R.A. The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator. Mini Rev. Med. Chem. 2006;6(5):603–609. doi: 10.2174/138955706776876203. [PubMed] [Cross Ref]
41. Vaajanen A., Vapaatalo H., Kautiainen H., Oksala O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest. Ophthalmol. Vis. Sci. 2008;49(6):2557–2562. doi: 10.1167/iovs.07-1399. [PubMed] [Cross Ref]
42. Guang C., Phillips R.D., Jiang B., Milani F. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. Arch. Cardiovasc. Dis. 2012;105(6-7):373–385. doi: 10.1016/j.acvd.2012.02.010. [PubMed] [Cross Ref]
43. Ribeiro-Oliveira A., Jr, Nogueira A.I., Pereira R.M., Boas W.W., Dos Santos R.A., Simões e Silva A.C. The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 2008;4(4):787–803. [PMC free article] [PubMed]
44. Weber K.T. Aldosterone in congestive heart failure. N. Engl. J. Med. 2001;345(23):1689–1697. doi: 10.1056/NEJMra000050. [PubMed] [Cross Ref]
45. Masuyer G., Yates C.J., Sturrock E.D., Acharya K.R. Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biol. Chem. 2014;395(10):1135–1149. doi: 10.1515/hsz-2014-0157. [PubMed] [Cross Ref]
46. Ferrão F.M., Lara L.S., Lowe J. Renin-angiotensin system in the kidney: What is new? World J. Nephrol. 2014;3(3):64–76. doi: 10.5527/wjn.v3.i3.64. [PMC free article] [PubMed] [Cross Ref]
47. Persson P.B. Renin: origin, secretion and synthesis. J. Physiol. 2003;552(Pt 3):667–671. doi: 10.1113/jphysiol.2003.049890. [PubMed] [Cross Ref]
48. Nguyen G., Delarue F., Burcklé C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002;109(11):1417–1427. doi: 10.1172/JCI0214276. [PMC free article] [PubMed] [Cross Ref]
49. Boucher R., Demassieux S., Garcia R., Genest J. Tonin, angiotensin II system. A review. Circ. Res. 1977;41(4) Suppl. 2:26–29. doi: 10.1161/01.RES.41.4.26. [PubMed] [Cross Ref]
50. Arakawa K. Serine protease angiotensin II systems. J. Hypertens. Suppl. 1996;14(5):S3–S7. [PubMed]
51. Maruta H., Arakawa K. Confirmation of direct angiotensin formation by kallikrein. Biochem. J. 1983;213(1):193–200. doi: 10.1042/bj2130193. [PubMed] [Cross Ref]
52. Tonnesen M.G., Klempner M.S., Austen K.F., Wintroub B.U. Identification of a human neutrophil angiotension II-generating protease as cathepsin G. J. Clin. Invest. 1982;69(1):25–30. doi: 10.1172/JCI110437. [PMC free article] [PubMed] [Cross Ref]
53. Becari C., Oliveira E.B., Salgado M.C. Alternative pathways for angiotensin II generation in the cardiovascular system. Braz. J. Med. Biol. Res. 2011;44(9):914–919. doi: 10.1590/S0100-879X2011007500093. [PubMed] [Cross Ref]
54. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 1990;66(4):883–890. doi: 10.1161/01.RES.66.4.883. [PubMed] [Cross Ref]
55. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990;265(36):22348–22357. [PubMed]
56. Parkin E.T., Turner A.J., Hooper N.M. Secretase-mediated cell surface shedding of the angiotensin-converting enzyme. Protein Pept. Lett. 2004;11(5):423–432. doi: 10.2174/0929866043406544. [PubMed] [Cross Ref]
57. Hooper N.M., Turner A.J. An ACE structure. Nat. Struct. Biol. 2003;10(3):155–157. doi: 10.1038/nsb0303-155. [PubMed] [Cross Ref]
58. Balyasnikova I.V., Karran E.H., Albrecht R.F., II, Danilov S.M. Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface. Biochem. J. 2002;362(Pt 3):585–595. doi: 10.1042/bj3620585. [PubMed] [Cross Ref]
59. Lew R.A. The zinc metallopeptidase family: new faces, new functions. Protein Pept. Lett. 2004;11(5):407–414. doi: 10.2174/0929866043406481. [PubMed] [Cross Ref]
60. Riordan J.F. Angiotensin-I-converting enzyme and its relatives. Genome Biol. 2003;4(8):225. doi: 10.1186/gb-2003-4-8-225. [PMC free article] [PubMed] [Cross Ref]
61. Campbell D.J. Circulating and tissue angiotensin systems. J. Clin. Invest. 1987;79(1):1–6. doi: 10.1172/JCI112768. [PMC free article] [PubMed] [Cross Ref]
62. Balcells E., Meng Q.C., Johnson W.H., Jr, Oparil S., Dell’Italia L.J. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol. 1997;273(4 Pt 2):H1769–H1774. [PubMed]
63. Takai S., Sakaguchi M., Jin D., Yamada M., Kirimura K., Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin. Chim. Acta. 2001;305(1-2):191–195. doi: 10.1016/S0009-8981(01)00379-5. [PubMed] [Cross Ref]
64. Miyazaki M., Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J. Pharmacol. Sci. 2006;100(5):391–397. doi: 10.1254/jphs.CPJ06008X. [PubMed] [Cross Ref]
65. Resende M.M., Mill J.G. Alternate angiotensin II-forming pathways and their importance in physiological or physiopathological conditions. Arq. Bras. Cardiol. 2002;78(4):425–438. doi: 10.1590/S0066-782X2002000400012. [PubMed] [Cross Ref]
66. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med. Sci. Monit. 2005;11(6):RA194–RA205. [PubMed]
67. Culman J., Höhle S., Qadri F., Edling O., Blume A., Lebrun C., Unger T. Angiotensin as neuromodulator/neurotransmitter in central control of body fluid and electrolyte homeostasis. Clin. Exp. Hypertens. 1995;17(1-2):281–293. doi: 10.3109/10641969509087071. [PubMed] [Cross Ref]
68. Qi G.M., Jia L.X., Li Y.L., Li H.H., Du J. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology. 2014;155(6):2254–2265. doi: 10.1210/en.2013-2011. [PubMed] [Cross Ref]
69. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000;52(3):415–472. [PubMed]
70. Albiston A.L., Peck G.R., Yeatman H.R., Fernando R., Ye S., Chai S.Y. Therapeutic targeting of insulin-regulated aminopeptidase: heads and tails? Pharmacol. Ther. 2007;116(3):417–427. doi: 10.1016/j.pharmthera.2007.07.006. [PubMed] [Cross Ref]
71. Chai S.Y., Fernando R., Peck G., Ye S.Y., Mendelsohn F.A., Jenkins T.A., Albiston A.L. The angiotensin IV/AT4 receptor. Cell. Mol. Life Sci. 2004;61(21):2728–2737. doi: 10.1007/s00018-004-4246-1. [PubMed] [Cross Ref]
72. Li X.C., Campbell D.J., Ohishi M., Yuan S., Zhuo J.L. AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Am. J. Physiol. Renal Physiol. 2006;290(5):F1024–F1033. doi: 10.1152/ajprenal.00221.2005. [PMC free article] [PubMed] [Cross Ref]
73. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000;87(5):E1–E9. doi: 10.1161/01.RES.87.5.e1. [PubMed] [Cross Ref]
74. Jackman H.L., Massad M.G., Sekosan M., et al. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension. 2002;39(5):976–981. doi: 10.1161/01.HYP.0000017283.67962.02. [PubMed] [Cross Ref]
75. Kokkonen J.O., Saarinen J., Kovanen P.T. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation. 1997;95(6):1455–1463. doi: 10.1161/01.CIR.95.6.1455. [PubMed] [Cross Ref]
76. Ocaranza M.P., Michea L., Chiong M., Lagos C.F., Lavandero S., Jalil J.E. Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clin. Sci. 2014;127(9):549–557. doi: 10.1042/CS20130449. [PubMed] [Cross Ref]
77. Mogielnicki A., Kramkowski K., Chabielska E., Buczko W. Angiotensin 1-9 influences hemodynamics and hemostatics parameters in rats. Pol. J. Pharmacol. 2003;55:503–504.
78. Garabelli P.J., Modrall J.G., Penninger J.M., Ferrario C.M., Chappell M.C. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp. Physiol. 2008;93(5):613–621. doi: 10.1113/expphysiol.2007.040246. [PMC free article] [PubMed] [Cross Ref]
79. McKinney C.A., Fattah C., Loughrey C.M., Milligan G., Nicklin S.A. Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin. Sci. 2014;126(12):815–827. doi: 10.1042/CS20130436. [PubMed] [Cross Ref]
80. Xia H., Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr. Hypertens. Rep. 2010;12(3):170–175. doi: 10.1007/s11906-010-0105-7. [PMC free article] [PubMed] [Cross Ref]
81. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000;275(43):33238–33243. doi: 10.1074/jbc.M002615200. [PubMed] [Cross Ref]
82. Guy J.L., Lambert D.W., Warner F.J., Hooper N.M., Turner A.J. Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim. Biophys. Acta. 2005;1751(1):2–8. doi: 10.1016/j.bbapap.2004.10.010. [PubMed] [Cross Ref]
83. Rice G.I., Thomas D.A., Grant P.J., Turner A.J., Hooper N.M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 2004;383(Pt 1):45–51. doi: 10.1042/BJ20040634. [PubMed] [Cross Ref]
84. Santos R.A., Ferreira A.J., Verano-Braga T., Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol. 2013;216(2):R1–R17. doi: 10.1530/JOE-12-0341. [PubMed] [Cross Ref]
85. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002;277(17):14838–14843. doi: 10.1074/jbc.M200581200. [PubMed] [Cross Ref]
86. Dilauro M., Burns K.D. Angiotensin-(1-7) and its effects in the kidney. Sci. World J. 2009;9:522–535. doi: 10.1100/tsw.2009.70. [PubMed] [Cross Ref]
87. Varagic J., Trask A.J., Jessup J.A., Chappell M.C., Ferrario C.M. New angiotensins. J. Mol. Med. (Berl.) 2008;86(6):663–671. doi: 10.1007/s00109-008-0340-4. [PMC free article] [PubMed] [Cross Ref]
88. Bader M. ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch. 2013;465(1):79–85. doi: 10.1007/s00424-012-1120-0. [PubMed] [Cross Ref]
89. Young D., Waitches G., Birchmeier C., Fasano O., Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986;45(5):711–719. doi: 10.1016/0092-8674(86)90785-3. [PubMed] [Cross Ref]
90. Young D., O’Neill K., Jessell T., Wigler M. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proc. Natl. Acad. Sci. USA. 1988;85(14):5339–5342. doi: 10.1073/pnas.85.14.5339. [PubMed] [Cross Ref]
91. Kitaoka T., Sharif M., Hanley M.R., Hjelmeland L.M. Expression of the MAS proto-oncogene in the retinal pigment epithelium of the rhesus macaque. Curr. Eye Res. 1994;13(5):345–351. doi: 10.3109/02713689409167298. [PubMed] [Cross Ref]
92. Iwata M., Cowling R.T., Gurantz D., Moore C., Zhang S., Yuan J.X., Greenberg B.H. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 2005;289(6):H2356–H2363. doi: 10.1152/ajpheart.00317.2005. [PubMed] [Cross Ref]
93. Vaajanen A., Kalesnykas G., Vapaatalo H., Uusitalo H. The expression of Mas-receptor of the renin-angiotensin system in the human eye. Graefes Arch. Clin. Exp. Ophthalmol. 2015;253(7):1053–1059. doi: 10.1007/s00417-015-2952-z. [PMC free article] [PubMed] [Cross Ref]
94. Ferrario C.M., Martell N., Yunis C., Flack J.M., Chappell M.C., Brosnihan K.B., Dean R.H., Fernandez A., Novikov S.V., Pinillas C., Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am. J. Hypertens. 1998;11(2):137–146. doi: 10.1016/S0895-7061(97)00400-7. [PubMed] [Cross Ref]
95. Luque M., Martin P., Martell N., Fernandez C., Brosnihan K.B., Ferrario C.M. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J. Hypertens. 1996;14(6):799–805. doi: 10.1097/00004872-199606000-00017. [PubMed] [Cross Ref]
96. Simões e Silva A.C., Diniz J.S., Pereira R.M., Pinheiro S.V., Santos R.A. Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr. Res. 2006;60(6):734–739. doi: 10.1203/01.pdr.0000246100.14061.bc. [PubMed] [Cross Ref]
97. Simões e Silva A. Pathophysiology of arterial hypertension: Insights from pediatric studies. Curr. Pediatr. Rev. 2006;2:209–223. doi: 10.2174/157339606778019684. [Cross Ref]
98. Simões E Silva A.C., Diniz J.S., Regueira Filho A., Santos R.A. The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J. Pediatr. 2004;145(1):93–98. doi: 10.1016/j.jpeds.2004.03.055. [PubMed] [Cross Ref]
99. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 2003;14(6):274–281. doi: 10.1016/S1043-2760(03)00111-5. [PubMed] [Cross Ref]
100. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., Cooper M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41(3):392–397. doi: 10.1161/01.HYP.0000060689.38912.CB. [PubMed] [Cross Ref]
101. Dias J., Axelband F., Lara L.S., Muzi-Filho H., Vieyra A. Is angiotensin-(3-4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system? J. Renin Angiotensin Aldosterone Syst. 2017;18(1):1470320316689338. doi: 10.1177/1470320316689338. [PubMed] [Cross Ref]
102. Ganten D., Marquez-Julio A., Granger P., Hayduk K., Karsunky K.P., Boucher R., Genest J. Renin in dog brain. Am. J. Physiol. 1971;221(6):1733–1737. [PubMed]
103. Watkins R.W., Baum T., Cedeno K., Smith E.M., Yuen P.H., Ahn H.S., Barnett A. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. J. Ocul. Pharmacol. 1987;3(4):295–307. doi: 10.1089/jop.1987.3.295. [PubMed] [Cross Ref]
104. Holappa M., Valjakka J., Vaajanen A. Angiotensin(1-7) and ACE2, “the hot spots” of renin-angiotensin system, detected in the human aqueous humor. Open Ophthalmol. J. 2015;9:28–32. doi: 10.2174/1874364101509010028. [PMC free article] [PubMed] [Cross Ref]
105. White A.J., Cheruvu S.C., Sarris M., Liyanage S.S., Lumbers E., Chui J., Wakefield D., McCluskey P.J. Expression of classical components of the renin-angiotensin system in the human eye. J. Renin Angiotensin Aldosterone Syst. 2015;16(1):59–66. doi: 10.1177/1470320314549791. [PubMed] [Cross Ref]
106. Sramek S.J., Wallow I.H., Day R.P., Ehrlich E.N. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest. Ophthalmol. Vis. Sci. 1988;29(11):1749–1752. [PubMed]
107. Wallow I.H., Sramek S.J., Bindley C.D., Darjatmoko S.R., Gange S.J. Ocular renin angiotensin: EM immunocytochemical localization of prorenin. Curr. Eye Res. 1993;12(10):945–950. doi: 10.3109/02713689309020401. [PubMed] [Cross Ref]
108. Berka J.L., Stubbs A.J., Wang D.Z., DiNicolantonio R., Alcorn D., Campbell D.J., Skinner S.L. Renin-containing Müller cells of the retina display endocrine features. Invest. Ophthalmol. Vis. Sci. 1995;36(7):1450–1458. [PubMed]
109. Chowdhury U.R., Madden B.J., Charlesworth M.C., Fautsch M.P. Proteome analysis of human aqueous humor. Invest. Ophthalmol. Vis. Sci. 2010;51(10):4921–4931. doi: 10.1167/iovs.10-5531. [PMC free article] [PubMed] [Cross Ref]
110. Sramek S.J., Wallow I.H., Tewksbury D.A., Brandt C.R., Poulsen G.L. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest. Ophthalmol. Vis. Sci. 1992;33(5):1627–1632. [PubMed]
111. Savaskan E., Löffler K.U., Meier F., Müller-Spahn F., Flammer J., Meyer P. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res. 2004;36(6):312–320. doi: 10.1159/000081633. [PubMed] [Cross Ref]
112. Vita J.B., Anderson J.A., Hulem C.D., Leopold I.H. Angiotensin-converting enzyme activity in ocular fluids. Invest. Ophthalmol. Vis. Sci. 1981;20(2):255–257. [PubMed]
113. Weinreb R.N., Polansky J.R., Kramer S.G., Baxter J.D. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest. Ophthalmol. Vis. Sci. 1985;26(2):170–175. [PubMed]
114. Aydin E., Demir H.D., Sahin S. Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy. Curr. Eye Res. 2010;35(3):230–234. doi: 10.3109/02713680903484242. [PubMed] [Cross Ref]
115. Ferrari-Dileo G., Ryan J.W., Rockwood E.J., Davis E.B., Anderson D.R. Angiotensin-converting enzyme in bovine, feline, and human ocular tissues. Invest. Ophthalmol. Vis. Sci. 1988;29(6):876–881. [PubMed]
116. Igić R., Kojović V. Angiotensin I converting enzyme (kininase II) in ocular tissues. Exp. Eye Res. 1980;30(3):299–303. doi: 10.1016/0014-4835(80)90010-X. [PubMed] [Cross Ref]
117. Danser A.H., Derkx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. 1994;35(3):1008–1018. [PubMed]
118. Osusky R., Nussberger J., Amstutz C., Flammer J., Brunner H.R. Individual measurements of angiotensin II concentrations in aqueous humor of the eye. Eur. J. Ophthalmol. 1994;4(4):228–233. [PubMed]
119. Senanayake Pd., Drazba J., Shadrach K., Milsted A., Rungger-Brandle E., Nishiyama K., Miura S., Karnik S., Sears J.E., Hollyfield J.G. Angiotensin II and its receptor subtypes in the human retina. Invest. Ophthalmol. Vis. Sci. 2007;48(7):3301–3311. doi: 10.1167/iovs.06-1024. [PubMed] [Cross Ref]
120. Lin C., Stone R.A., Wax M.B. Angiotensin binding sites in rabbit anterior uvea and human ciliary epithelial cells. Invest. Ophthalmol. Vis. Sci. 1990;31(1):147–152. [PubMed]
121. Lograno M.D., Reibaldi A. Receptor-responses in fresh human ciliary muscle. Br. J. Pharmacol. 1986;87(2):379–385. doi: 10.1111/j.1476-5381.1986.tb10827.x. [PMC free article] [PubMed] [Cross Ref]
122. Cullinane A.B., Leung P.S., Ortego J., Coca-Prados M., Harvey B.J. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br. J. Ophthalmol. 2002;86(6):676–683. doi: 10.1136/bjo.86.6.676. [PMC free article] [PubMed] [Cross Ref]
123. Holappa M., Vapaatalo H., Vaajanen A. Ocular renin-angiotensin system with special reference in the anterior part of the eye. World J Ophthalmol. 2015;5(3):110–112. doi: 10.5318/wjo.v5.i3.110. [Cross Ref]
124. Sharma O.P., Vita J.B. Determination of angiotensin-converting enzyme activity in tears. A noninvasive test for evaluation of ocular sarcoidosis. Arch. Ophthalmol. 1983;101(4):559–561. doi: 10.1001/archopht.1983.01040010559004. [PubMed] [Cross Ref]
125. Immonen I., Friberg K., Sorsila R., Fyhrquist F. Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis. Acta Ophthalmol. (Copenh.) 1987;65(1):27–29. doi: 10.1111/j.1755-3768.1987.tb08486.x. [PubMed] [Cross Ref]
126. Nakanishi T., Koyama R., Ikeda T., Shimizu A. Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002;776(1):89–100. doi: 10.1016/S1570-0232(02)00078-8. [PubMed] [Cross Ref]
127. Ishizaki E., Takai S., Ueki M., Maeno T., Maruichi M., Sugiyama T., Oku H., Ikeda T., Miyazaki M. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am. J. Ophthalmol. 2006;141(1):129–134. doi: 10.1016/j.ajo.2005.08.066. [PubMed] [Cross Ref]
128. Schelling P., Ganten U., Sponer G., Unger T., Ganten D. Components of the renin-angiotensin system in the cerebrospinal fluid of rats and dogs with special consideration of the origin and the fate of angiotensin II. Neuroendocrinology. 1980;31(5):297–308. doi: 10.1159/000123092. [PubMed] [Cross Ref]
129. Cunha-Vaz J. The blood-ocular barriers. Surv. Ophthalmol. 1979;23(5):279–296. doi: 10.1016/0039-6257(79)90158-9. [PubMed] [Cross Ref]
130. Ramirez M., Davidson E.A., Luttenauer L., Elena P.P., Cumin F., Mathis G.A., De Gasparo M. The renin-angiotensin system in the rabbit eye. J. Ocul. Pharmacol. Ther. 1996;12(3):299–312. doi: 10.1089/jop.1996.12.299. [PubMed] [Cross Ref]
131. Geng L., Persson K., Nilsson S.F. Angiotensin converting anzyme (ACE) activity in porcine ocular tissue: effects of diet and ACE inhibitors. J. Ocul. Pharmacol. Ther. 2003;19(6):589–598. doi: 10.1089/108076803322660503. [PubMed] [Cross Ref]
132. Costagliola C., Di Benedetto R., De Caprio L., Verde R., Mastropasqua L. Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur. J. Ophthalmol. 1995;5(1):19–25. [PubMed]
133. Shah G.B., Sharma S., Mehta A.A., Goyal R.K. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J. Cardiovasc. Pharmacol. 2000;36(2):169–175. doi: 10.1097/00005344-200008000-00005. [PubMed] [Cross Ref]
134. Costagliola C., Verolino M., De Rosa M.L., Iaccarino G., Ciancaglini M., Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp. Eye Res. 2000;71(2):167–171. doi: 10.1006/exer.2000.0866. [PubMed] [Cross Ref]
135. Wang R.F., Podos S.M., Mittag T.W., Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp. Eye Res. 2005;80(5):629–632. doi: 10.1016/j.exer.2004.11.012. [PubMed] [Cross Ref]
136. Inoue T., Yokoyoma T., Mori Y., Sasaki Y., Hosokawa T., Yanagisawa H., Koike H. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr. Eye Res. 2001;23(2):133–138. doi: 10.1076/ceyr.23.2.133.5473. [PubMed] [Cross Ref]
137. Giardina W.J., Kleinert H.D., Ebert D.M., Wismer C.T., Chekal M.A., Stein H.H. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals. J. Ocul. Pharmacol. 1990;6(2):75–83. doi: 10.1089/jop.1990.6.75. [PubMed] [Cross Ref]
138. Choudhary R., Kapoor M., Singh A., Bodakhe S. Therapeutic targets of renin-angiotensin system in ocular disorders. J. Curr. Ophthalmol.; 2016. pp. 1–10. [PMC free article] [PubMed]
139. Buys E.S., Potter L.R., Pasquale L.R., Ksander B.R. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Front. Mol. Neurosci. 2014;7:38. doi: 10.3389/fnmol.2014.00038. [PMC free article] [PubMed] [Cross Ref]
140. Gauthier A.C., Liu J. Neurodegeneration and neuroprotection in glaucoma. Yale J. Biol. Med. 2016;89(1):73–79. [PMC free article] [PubMed]
141. Khawaja A.P., Chan M.P., Broadway D.C., Garway-Heath D.F., Luben R., Yip J.L., Hayat S., Wareham N.J., Khaw K.T., Foster P.J. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014;121(8):1501–1507. doi: 10.1016/j.ophtha.2014.02.009. [PMC free article] [PubMed] [Cross Ref]
142. McGwin G., Jr, McNeal S., Owsley C., Girkin C., Epstein D., Lee P.P. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch. Ophthalmol. 2004;122(6):822–826. doi: 10.1001/archopht.122.6.822. [PubMed] [Cross Ref]
143. Budenz D.L. A clinician’s guide to the assessment and management of nonadherence in glaucoma. Ophthalmology. 2009;116(11) Suppl.:S43–S47. doi: 10.1016/j.ophtha.2009.06.022. [PubMed] [Cross Ref]
144. Schwartz G.F., Quigley H.A. Adherence and persistence with glaucoma therapy. Surv. Ophthalmol. 2008;53(Suppl. 1):S57–S68. doi: 10.1016/j.survophthal.2008.08.002. [PubMed] [Cross Ref]
145. Gauthier A.C., Liu J. Epigenetics and Signaling Pathways in Glaucoma. Biomed. Res. Int. Available from: https://www.hindawi.com/journals/ bmri/2017/5712341/ . 2017 doi: 10.1155/2017/5712341. 2017: 5712341. [PMC free article] [PubMed] [Cross Ref]
146. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013. [PubMed] [Cross Ref]
147. Janssen S.F., Gorgels T.G., van der Spek P.J., Jansonius N.M., Bergen A.A. In silico analysis of the molecular machinery underlying aqueous humor production: potential implications for glaucoma. J. Clin. Bioinforma. 2013;3(1):21. doi: 10.1186/2043-9113-3-21. [PMC free article] [PubMed] [Cross Ref]
148. Civan M.M., Macknight A.D. The ins and outs of aqueous humour secretion. Exp. Eye Res. 2004;78(3):625–631. doi: 10.1016/j.exer.2003.09.021. [PubMed] [Cross Ref]
149. Brubaker R.F. The flow of aqueous humor in the human eye. Trans. Am. Ophthalmol. Soc. 1982;80:391–474. [PMC free article] [PubMed]
150. Baskaran M., Raman K., Ramani K.K., Roy J., Vijaya L., Badrinath S.S. Intraocular pressure changes and ocular biometry during Sirsasana (headstand posture) in yoga practitioners. Ophthalmology. 2006;113(8):1327–1332. doi: 10.1016/j.ophtha.2006.02.063. [PubMed] [Cross Ref]
151. Dane S., Koçer I., Demirel H., Uçok K., Tan U. Long-term effects of mild exercise on intraocular pressure in athletes and sedentary subjects. Int. J. Neurosci. 2006;116(10):1207–1214. doi: 10.1080/00207450500516461. [PubMed] [Cross Ref]
152. Dane S., Koçer I., Demirel H., Ucok K., Tan U. Effect of acute submaximal exercise on intraocular pressure in athletes and sedentary subjects. Int. J. Neurosci. 2006;116(10):1223–1230. doi: 10.1080/00207450500522501. [PubMed] [Cross Ref]
153. Marcus D.F., Krupin T., Podos S.M., Becker B. The effect of exercise on intraocular pressure. I. Human beings. Invest. Ophthalmol. 1970;9(10):749–752. [PubMed]
154. Vieira G.M., Oliveira H.B., de Andrade D.T., Bottaro M., Ritch R. Intraocular pressure variation during weight lifting. Arch. Ophthalmol. 2006;124(9):1251–1254. doi: 10.1001/archopht.124.9.1251. [PubMed] [Cross Ref]
155. Mark H.H. Aqueous humor dynamics in historical perspective. Surv. Ophthalmol. 2010;55(1):89–100. doi: 10.1016/j.survophthal.2009.06.005. [PubMed] [Cross Ref]
156. Goel M., Picciani R.G., Lee R.K., Bhattacharya S.K. Aqueous humor dynamics: a review. Open Ophthalmol. J. 2010;4:52–59. doi: 10.2174/1874364101004010052. [PMC free article] [PubMed] [Cross Ref]
157. To C.H., Kong C.W., Chan C.Y., Shahidullah M., Do C.W. The mechanism of aqueous humour formation. Clin. Exp. Optom. 2002;85(6):335–349. doi: 10.1111/j.1444-0938.2002.tb02384.x. [PubMed] [Cross Ref]
158. Freddo T.F. The Glenn A. Fry Award Lecture 1992: aqueous humor proteins: a key for unlocking glaucoma? Optom. Vis. Sci. 1993;70(4):263–270. doi: 10.1097/00006324-199304000-00003. [PubMed] [Cross Ref]
159. McLaren J.W., Ziai N., Brubaker R.F. A simple three-compartment model of anterior segment kinetics. Exp. Eye Res. 1993;56(3):355–366. doi: 10.1006/exer.1993.1046. [PubMed] [Cross Ref]
160. Barsotti M.F., Bartels S.P., Freddo T.F., Kamm R.D. The source of protein in the aqueous humor of the normal monkey eye. Invest. Ophthalmol. Vis. Sci. 1992;33(3):581–595. [PubMed]
161. Freddo T.F., Bartels S.P., Barsotti M.F., Kamm R.D. The source of proteins in the aqueous humor of the normal rabbit. Invest. Ophthalmol. Vis. Sci. 1990;31(1):125–137. [PubMed]
162. Millar J., True Gablet B., Kaufman P. Aqueous humor dynamics. A review. Open Optho. J. 2010;4:52–59.
163. Hou Y., Delamere N.A. Influence of ANG II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium. Am. J. Physiol. Cell Physiol. 2002;283(2):C552–C559. doi: 10.1152/ajpcell.00459.2001. [PubMed] [Cross Ref]
164. Cousins S.W., McCabe M.M., Danielpour D., Streilein J.W. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophthalmol. Vis. Sci. 1991;32(8):2201–2211. [PubMed]
165. Becker B. Vanadate and aqueous humor dynamics. Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 1980;19(10):1156–1165. [PubMed]
166. Caprioli J. The ciliary epithelia and aqueous humor. In: Hart W.M., editor. Adler’s Physiology of the eye. 9th ed. St. Louis: Mosby-Year book Inc; 1992. pp. 118–147.
167. Yamaguchi Y., Watanabe T., Hirakata A., Hida T. Localization and ontogeny of aquaporin-1 and -4 expression in iris and ciliary epithelial cells in rats. Cell Tissue Res. 2006;325(1):101–109. doi: 10.1007/s00441-005-0122-z. [PubMed] [Cross Ref]
168. Wistrand P.J. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol. Scand. 1951;24(2-3):145–148. doi: 10.1111/j.1748-1716.1951.tb00833.x. [PubMed] [Cross Ref]
169. Tsukaguchi H., Tokui T., Mackenzie B., Berger U.V., Chen X.Z., Wang Y., Brubaker R.F., Hediger M.A. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999;399(6731):70–75. doi: 10.1038/19986. [PubMed] [Cross Ref]
170. Reddy V.N. Dynamics of transport systems in the eye. Friedenwald Lecture. Invest. Ophthalmol. Vis. Sci. 1979;18(10):1000–1018. [PubMed]
171. Fitt A.D., Gonzalez G. Fluid mechanics of the human eye: aqueous humour flow in the anterior chamber. Bull. Math. Biol. 2006;68(1):53–71. doi: 10.1007/s11538-005-9015-2. [PubMed] [Cross Ref]
172. Murray D.L., Bartels S.P. The relationship between aqueous humor flow and anterior chamber protein concentration in rabbits. Invest. Ophthalmol. Vis. Sci. 1993;34(2):370–376. [PubMed]
173. Lütjen-Drecoll E., Gabelt B.T., Tian B., Kaufman P.L. Outflow of aqueous humor. J. Glaucoma. 2001;10(5) Suppl. 1:S42–S44. doi: 10.1097/00061198-200110001-00016. [PubMed] [Cross Ref]
174. Tamm E.R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res. 2009;88(4):648–655. doi: 10.1016/j.exer.2009.02.007. [PubMed] [Cross Ref]
175. Tan J.C., Peters D.M., Kaufman P.L. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr. Opin. Ophthalmol. 2006;17(2):168–174. [PubMed]
176. Brubaker R.F. Measurement of uveoscleral outflow in humans. J. Glaucoma. 2001;10(5) Suppl. 1:S45–S48. doi: 10.1097/00061198-200110001-00017. [PubMed] [Cross Ref]
177. Johnson M. ‘What controls aqueous humour outflow resistance?’. Exp. Eye Res. 2006;82(4):545–557. doi: 10.1016/j.exer.2005.10.011. [PMC free article] [PubMed] [Cross Ref]
178. Bill A. Some aspects of aqueous humour drainage. Eye (Lond.) 1993;7(Pt 1):14–19. doi: 10.1038/eye.1993.4. [PubMed] [Cross Ref]
179. Alm A., Nilsson S.F. Uveoscleral outflow--a review. Exp. Eye Res. 2009;88(4):760–768. doi: 10.1016/j.exer.2008.12.012. [PubMed] [Cross Ref]
180. Fautsch M.P., Johnson D.H. Aqueous humor outflow: what do we know? Where will it lead us? Invest. Ophthalmol. Vis. Sci. 2006;47(10):4181–4187. doi: 10.1167/iovs.06-0830. [PMC free article] [PubMed] [Cross Ref]
181. Nilsson S.F. The uveoscleral outflow routes. Eye (Lond.) 1997;11(Pt 2):149–154. doi: 10.1038/eye.1997.43. [PubMed] [Cross Ref]
182. Yücel Y.H., Johnston M.G., Ly T., Patel M., Drake B., Gümüş E., Fraenkl S.A., Moore S., Tobbia D., Armstrong D., Horvath E., Gupta N. Identification of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic” outflow pathway. Exp. Eye Res. 2009;89(5):810–819. doi: 10.1016/j.exer.2009.08.010. [PubMed] [Cross Ref]
183. Weinreb R.N. Uveoscleral outflow: the other outflow pathway. J. Glaucoma. 2000;9(5):343–345. doi: 10.1097/00061198-200010000-00001. [PubMed] [Cross Ref]
184. Zhang K., Zhang L., Weinreb R.N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 2012;11(7):541–559. doi: 10.1038/nrd3745. [PubMed] [Cross Ref]
185. Mehta A., Iyer L., Parmar S., Shah G., Goyal R. Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can. J. Physiol. Pharmacol. 2010;88(5):595–600. doi: 10.1139/Y10-026. [PubMed] [Cross Ref]
186. Inoue T., Yokoyoma T., Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr. Eye Res. 2001;23(2):139–143. doi: 10.1076/ceyr.23.2.139.5470. [PubMed] [Cross Ref]
187. Shen F., Zhang L., Liu T. [Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells]. Yan Ke Xue Bao. 2001;17(4):209–212. [PubMed]
188. Reitsamer H.A., Kiel J.W. Relationship between ciliary blood flow and aqueous production in rabbits. Invest. Ophthalmol. Vis. Sci. 2003;44(9):3967–3971. doi: 10.1167/iovs.03-0088. [PubMed] [Cross Ref]
189. Lotti V.J., Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J. Ocul. Pharmacol. 1990;6(1):1–7. doi: 10.1089/jop.1990.6.1. [PubMed] [Cross Ref]
190. Nilsson S.F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 1989;48(5):707–716. doi: 10.1016/0014-4835(89)90011-0. [PubMed] [Cross Ref]
191. Weinreb R.N., Toris C.B., Gabelt B.T., Lindsey J.D., Kaufman P.L. Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. 2002;47(Suppl. 1):S53–S64. doi: 10.1016/S0039-6257(02)00306-5. [PubMed] [Cross Ref]
192. Momose N., Fukuo K., Morimoto S., Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993;21(6 Pt 2):921–924. doi: 10.1161/01.HYP.21.6.921. [PubMed] [Cross Ref]
193. Haefliger I.O., Flammer J., Lüscher T.F. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest. Ophthalmol. Vis. Sci. 1992;33(7):2340–2343. [PubMed]
194. Yao K., Tschudi M., Flammer J., Lüscher T.F. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. Invest. Ophthalmol. Vis. Sci. 1991;32(6):1791–1798. [PubMed]
195. Quigley H.A., Pitha I.F., Welsbie D.S., Nguyen C., Steinhart M.R., Nguyen T.D., Pease M.E., Oglesby E.N., Berlinicke C.A., Mitchell K.L., Kim J., Jefferys J.J., Kimball E.C. Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. PLoS One. 2015;10(10):e0141137. doi: 10.1371/journal.pone.0141137. [PMC free article] [PubMed] [Cross Ref]
196. Yang H., Hirooka K., Fukuda K., Shiraga F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest. Ophthalmol. Vis. Sci. 2009;50(12):5800–5804. doi: 10.1167/iovs.09-3678. [PubMed] [Cross Ref]
197. Sharif N.A. Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. J. Ocul. Pharmacol. Ther. 2015;31(3):131–145. doi: 10.1089/jop.2014.0114. [PubMed] [Cross Ref]
198. Foureaux G., Nogueira B.S., Coutinho D.C., Raizada M.K., Nogueira J.C., Ferreira A.J. Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina. Braz. J. Med. Biol. Res. 2015;48(12):1109–1114. doi: 10.1590/1414-431X20154583. [PMC free article] [PubMed] [Cross Ref]
199. Solinski H.J., Gudermann T., Breit A. Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol. Rev. 2014;66(3):570–597. doi: 10.1124/pr.113.008425. [PubMed] [Cross Ref]
200. Luhtala S., Vaajanen A., Oksala O., Valjakka J., Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J. Ocul. Pharmacol. Ther. 2009;25(1):23–28. doi: 10.1089/jop.2008.0081. [PubMed] [Cross Ref]
201. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA. 2003;100(14):8258–8263. doi: 10.1073/pnas.1432869100. [PubMed] [Cross Ref]
202. Macri F.J. The action of angiotensin on intraocular pressure. Arch. Ophthalmol. 1965;73:528–539. doi: 10.1001/archopht.1965.00970030530016. [PubMed] [Cross Ref]
203. Capponi A.M., Lew P.D., Jornot L., Vallotton M.B. Correlation between cytosolic free Ca2+ and aldosterone production in bovine adrenal glomerulosa cells. Evidence for a difference in the mode of action of angiotensin II and potassium. J. Biol. Chem. 1984;259(14):8863–8869. [PubMed]
204. Langman M.J., Lancashire R.J., Cheng K.K., Stewart P.M. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br. J. Ophthalmol. 2005;89(8):960–963. doi: 10.1136/bjo.2004.053397. [PMC free article] [PubMed] [Cross Ref]
205. Grunwald J.E., Riva C.E., Stone R.A., Keates E.U., Petrig B.L. Retinal autoregulation in open-angle glaucoma. Ophthalmology. 1984;91(12):1690–1694. doi: 10.1016/S0161-6420(84)34091-X. [PubMed] [Cross Ref]
206. Piltz-seymour J.R., Grunwald J.E., Hariprasad S.M., Dupont J. Optic nerve blood flow is diminished in eyes of primary open-angle glaucoma suspects. Am. J. Ophthalmol. 2001;132(1):63–69. doi: 10.1016/S0002-9394(01)00871-6. [PubMed] [Cross Ref]
207. Hayreh S.S., Zimmerman M.B., Podhajsky P., Alward W.L. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am. J. Ophthalmol. 1994;117(5):603–624. doi: 10.1016/S0002-9394(14)70067-4. [PubMed] [Cross Ref]
208. Marin Garcia P.J., Marin-Castaño M.E. Angiotensin II-related hypertension and eye diseases. World J. Cardiol. 2014;6(9):968–984. doi: 10.4330/wjc.v6.i9.968. [PMC free article] [PubMed] [Cross Ref]
209. Frank R.N. Diabetic retinopathy. N. Engl. J. Med. 2004;350(1):48–58. doi: 10.1056/NEJMra021678. [PubMed] [Cross Ref]
210. Harindhanavudhi T., Mauer M., Klein R., Zinman B., Sinaiko A., Caramori M.L., Renin Angiotensin System Study (RASS) group Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care. 2011;34(8):1838–1842. doi: 10.2337/dc11-0476. [PMC free article] [PubMed] [Cross Ref]
211. Bolinger M.T., Antonetti D.A. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int. J. Mol. Sci. 2016;17(9):E1498. doi: 10.3390/ijms17091498. [PMC free article] [PubMed] [Cross Ref]
212. Tarr J.M., Kaul K., Chopra M., Kohner E.M., Chibber R. Pathophysiology of diabetic retinopathy. 2013 doi: 10.1155/2013/343560. [PMC free article] [PubMed] [Cross Ref]
213. Sjølie A.K., Dodson P., Hobbs F.R. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int. J. Clin. Pract. 2011;65(2):148–153. doi: 10.1111/j.1742-1241.2010.02552.x. [PubMed] [Cross Ref]
214. Wilkinson C.P., Ferris F.L., III, Klein R.E., Lee P.P., Agardh C.D., Davis M., Dills D., Kampik A., Pararajasegaram R., Verdaguer J.T., Global Diabetic Retinopathy Project Group Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682. doi: 10.1016/S0161-6420(03)00475-5. [PubMed] [Cross Ref]
215. Ivanova T., Jalil A., Antoniou Y., Bishop P.N., Vallejo-Garcia J.L., Patton N. Vitrectomy for primary symptomatic vitreous opacities: an evidence-based review. Eye (Lond.) 2016;30(5):645–655. doi: 10.1038/eye.2016.30. [PMC free article] [PubMed] [Cross Ref]
216. Clermont A., Bursell S.E., Feener E.P. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl. 2006;24(1):S73–S80. doi: 10.1097/01.hjh.0000220410.69116.f8. [PubMed] [Cross Ref]
217. Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T., Drummond K., Donnelly S., Goodyer P., Gubler M.C., Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009;361(1):40–51. doi: 10.1056/NEJMoa0808400. [PMC free article] [PubMed] [Cross Ref]
218. Wilkinson-Berka J.L., Tan G., Jaworski K., Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 2007;20(4):423–430. doi: 10.1016/j.amjhyper.2006.09.018. [PubMed] [Cross Ref]
219. Funatsu H., Yamashita H., Nakanishi Y., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 2002;86(3):311–315. doi: 10.1136/bjo.86.3.311. [PMC free article] [PubMed] [Cross Ref]
220. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol. 2002;133(4):537–543. doi: 10.1016/S0002-9394(02)01323-5. [PubMed] [Cross Ref]
221. Schiffman R., Fisher L., Nussbaum J., Edwards P., Scicli G. Prorenin and renin levels in the vitreous of human eyes with and without proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1992;33:1362.
222. Nagisa Y., Shintani A., Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia. 2001;44(7):883–888. doi: 10.1007/s001250100556. [PubMed] [Cross Ref]
223. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998;82(5):619–628. doi: 10.1161/01.RES.82.5.619. [PubMed] [Cross Ref]
224. Fernandez L.A., Twickler J., Mead A. Neovascularization produced by angiotensin II. J. Lab. Clin. Med. 1985;105(2):141–145. [PubMed]
225. Aiello L.P., Bursell S.E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E., King G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46(9):1473–1480. doi: 10.2337/diab.46.9.1473. [PubMed] [Cross Ref]
226. Haque R., Hur E.H., Farrell A.N., Iuvone P.M., Howell J.C. MicroRNA-152 represses VEGF and TGFβ1 expressions through post-transcriptional inhibition of (Pro)renin receptor in human retinal endothelial cells. Mol. Vis. 2015;21:224–235. [PMC free article] [PubMed]
227. Kanda A., Ishida S. The vitreous renin–angiotensin system is mediated by soluble (pro)renin receptor in diabetic retinopathy: A new implication of the receptor-associated prorenin system. Taiwan J. Ophthalmol. 2013;3:51–53. doi: 10.1016/j.tjo.2013.04.004. [Cross Ref]
228. Kanda A., Noda K., Saito W., Ishida S. (Pro) renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. Diabetologia. 2012;55(11):3104–3113. doi: 10.1007/s00125-012-2702-2. [PubMed] [Cross Ref]
229. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., Tsubota K., Itoh H., Oike Y., Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes. 2009;58(7):1625–1633. doi: 10.2337/db08-0254. [PMC free article] [PubMed] [Cross Ref]
230. Vincent F., Bonnin P., Clemessy M., Contrerès J.O., Lamandé N., Gasc J.M., Vilar J., Hainaud P., Tobelem G., Corvol P., Dupuy E. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 2009;69(7):2853–2860. doi: 10.1158/0008-5472.CAN-08-2484. [PubMed] [Cross Ref]
231. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 1998;338(10):645–652. doi: 10.1056/NEJM199803053381003. [PubMed] [Cross Ref]
232. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [PubMed] [Cross Ref]
233. Jonas J.B., Hayreh S.S., Martus P. Influence of arterial hypertension and diet-induced atherosclerosis on macular drusen. Graefes Arch. Clin. Exp. Ophthalmol. 2003;241(2):125–134. doi: 10.1007/s00417-002-0615-3. [PubMed] [Cross Ref]
234. Wang B., Wang F., Zhang Y., Zhao S.H., Zhao W.J., Yan S.L., Wang Y.G. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–274. doi: 10.1016/S2213-8587(14)70256-6. [PubMed] [Cross Ref]
235. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713. doi: 10.1136/bmj.317.7160.703. [PMC free article] [PubMed] [Cross Ref]
236. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28–31. doi: 10.1016/S0140-6736(97)06209-0. [PubMed] [Cross Ref]
237. Satofuka S., Ichihara A., Nagai N., Koto T., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Itoh H., Oike Y., Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2007;48(1):422–429. doi: 10.1167/iovs.06-0534. [PubMed] [Cross Ref]
238. Fletcher E.L., Phipps J.A., Ward M.M., Vessey K.A., Wilkinson-Berka J.L. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog. Retin. Eye Res. 2010;29(4):284–311. doi: 10.1016/j.preteyeres.2010.03.003. [PubMed] [Cross Ref]
239. Nagai N., Oike Y., Izumi-Nagai K., Koto T., Satofuka S., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Ishida S. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest. Ophthalmol. Vis. Sci. 2007;48(5):2321–2326. doi: 10.1167/iovs.06-1296. [PubMed] [Cross Ref]
240. Praddaude F., Cousins S.W., Pêcher C., Marin-Castaño M.E. Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Exp. Eye Res. 2009;89(1):109–118. doi: 10.1016/j.exer.2009.02.020. [PMC free article] [PubMed] [Cross Ref]
241. Striker G.E., Praddaude F., Alcazar O., Cousins S.W., Marin-Castaño M.E. Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am. J. Physiol. Cell Physiol. 2008;295(6):C1633–C1646. doi: 10.1152/ajpcell.00092.2008. [PubMed] [Cross Ref]
242. Ishida S. [Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation]. Nippon Ganka Gakkai Zasshi. 2009;113(3):403–422. [PubMed]
243. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., Tsubota K., Itoh H., Oike Y., Ishida S. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am. J. Pathol. 2008;173(6):1911–1918. doi: 10.2353/ajpath.2008.080457. [PubMed] [Cross Ref]
244. Hikichi T., Mori F., Takamiya A., Sasaki M., Horikawa Y., Takeda M., Yoshida A. Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats. Am. J. Ophthalmol. 2001;132(4):587–589. doi: 10.1016/S0002-9394(01)01139-4. [PubMed] [Cross Ref]
245. Nagai N., Oike Y., Izumi-Nagai K., Urano T., Kubota Y., Noda K., Ozawa Y., Inoue M., Tsubota K., Suda T., Ishida S. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler. Thromb. Vasc. Biol. 2006;26(10):2252–2259. doi: 10.1161/01.ATV.0000240050.15321.fe. [PubMed] [Cross Ref]
246. Nabah Y.N., Mateo T., Estellés R., Mata M., Zagorski J., Sarau H., Cortijo J., Morcillo E.J., Jose P.J., Sanz M.J. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581–3586. doi: 10.1161/01.CIR.0000148824.93600.F3. [PubMed] [Cross Ref]
247. Buschini E., Fea A.M., Lavia C.A., Nassisi M., Pignata G., Zola M., Grignolo F.M. Recent developments in the management of dry age-related macular degeneration. Clin. Ophthalmol. 2015;9:563–574. doi: 10.2147/OPTH.S59724. [PMC free article] [PubMed] [Cross Ref]
248. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch. Ophthalmol. 2001;119(8):1110–1118. doi: 10.1001/archopht.119.8.1110. [PubMed] [Cross Ref]
249. Lutty G.A., Chan-Ling T., Phelps D.L., Adamis A.P., Berns K.I., Chan C.K., Cole C.H., D’Amore P.A., Das A., Deng W.T., Dobson V., Flynn J.T., Friedlander M., Fulton A., Good W.V., Grant M.B., Hansen R., Hauswirth W.W., Hardy R.J., Hinton D.R., Hughes S., McLeod D.S., Palmer E.A., Patz A., Penn J.S., Raisler B.J., Repka M.X., Saint-Geniez M., Shaw L.C., Shima D.T., Smith B.T., Smith L.E., Tahija S.G., Tasman W., Trese M.T. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol. Vis. 2006;12:532–580. [PubMed]
250. Autrata R., Senková K., Holousová M., Krejcírová I., Dolezel Z., Borek I. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Cesk. Slov. Oftalmol. 2012;68(1):29–36. [PubMed]
251. Beharry K.D., Valencia G.B., Lazzaro D.R., Aranda J.V. Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity. Semin. Perinatol. 2016;40(3):189–202. doi: 10.1053/j.semperi.2015.12.006. [PMC free article] [PubMed] [Cross Ref]
252. Yokota H., Nagaoka T., Mori F., Hikichi T., Hosokawa H., Tanaka H., Ishida Y., Suzuki F., Yoshida A. Prorenin levels in retinopathy of prematurity. Am. J. Ophthalmol. 2007;143(3):531–533. doi: 10.1016/j.ajo.2006.10.046. [PubMed] [Cross Ref]
253. Moravski C.J., Kelly D.J., Cooper M.E., Gilbert R.E., Bertram J.F., Shahinfar S., Skinner S.L., Wilkinson-Berka J.L. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000;36(6):1099–1104. doi: 10.1161/01.HYP.36.6.1099. [PubMed] [Cross Ref]
254. Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 2003;163(3):879–887. doi: 10.1016/S0002-9440(10)63448-7. [PubMed] [Cross Ref]
255. Downie L.E., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia. 2008;56(10):1076–1090. doi: 10.1002/glia.20680. [PubMed] [Cross Ref]
256. Lonchampt M., Pennel L., Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest. Ophthalmol. Vis. Sci. 2001;42(2):429–432. [PubMed]
257. Tadesse M., Yan Y., Yossuck P., Higgins R.D. Captopril improves retinal neovascularization via endothelin-1. Invest. Ophthalmol. Vis. Sci. 2001;42(8):1867–1872. [PubMed]
258. Otani A., Takagi H., Oh H., Suzuma K., Matsumura M., Ikeda E., Honda Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest. Ophthalmol. Vis. Sci. 2000;41(5):1192–1199. [PubMed]

Articles from The Open Ophthalmology Journal are provided here courtesy of Bentham Science Publishers